Read the full blog: ThreeFlows Post GLP-1 drugs like Ozempic and Wegovy are transforming metabolic health and employer medical spend
Eli Lilly (LLY) Stock price: $883.88 Trailing 12-month (TTM) EPS: $6.79 EPS growth: 7.95% Dividend yield: 0.59% Business Overview Lilly makes drug treatments and sells them to customers around the world
This cluster provides the scientific roadmap to understand and rebuild that foundation
The protective effects of GLP-1 RAs against cardiovascular events have been demonstrated in several studies, thus supporting their application in patients with heart failure with preserved ejection fraction and DM2 ( Taken together, GLP-1 is a major metabolic and regulatory hormone, with many potential therapeutic implications beyond glycemic control, encompassing cardiovascular protection, enhanced renal function, and the potential benefits in hepatic disease
Telehealth regulations vary significantly by state some require synchronous video consultations, while others permit asynchronous review
However, the gut microbiome's influence on GLP-1 secretion is complexwhile certain bacterial metabolites like butyrate may support intestinal health, directly stimulating GLP-1 production through probiotics alone has not been validated in large-scale human trials
